175 related articles for article (PubMed ID: 37354827)
1. NOX2 inhibition stabilizes vulnerable plaques by enhancing macrophage efferocytosis via MertK/PI3K/AKT pathway.
Wang Y; Liu XY; Wang Y; Zhao WX; Li FD; Guo PR; Fan Q; Wu XF
Redox Biol; 2023 Aug; 64():102763. PubMed ID: 37354827
[TBL] [Abstract][Full Text] [Related]
2. Protective Functions of Liver X Receptor α in Established Vulnerable Plaques: Involvement of Regulating Endoplasmic Reticulum-Mediated Macrophage Apoptosis and Efferocytosis.
Che X; Xiao Q; Song W; Zhang H; Sun B; Geng N; Tao Z; Shao Q; Pu J
J Am Heart Assoc; 2021 May; 10(10):e018455. PubMed ID: 33969692
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II deteriorates advanced atherosclerosis by promoting MerTK cleavage and impairing efferocytosis through the AT
Zhang Y; Wang Y; Zhou D; Zhang LS; Deng FX; Shu S; Wang LJ; Wu Y; Guo N; Zhou J; Yuan ZY
Am J Physiol Cell Physiol; 2019 Oct; 317(4):C776-C787. PubMed ID: 31390228
[TBL] [Abstract][Full Text] [Related]
4. Mertk receptor mutation reduces efferocytosis efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of apoe-/- mice.
Thorp E; Cui D; Schrijvers DM; Kuriakose G; Tabas I
Arterioscler Thromb Vasc Biol; 2008 Aug; 28(8):1421-8. PubMed ID: 18451332
[TBL] [Abstract][Full Text] [Related]
5. Melatonin stabilizes rupture-prone vulnerable plaques via regulating macrophage polarization in a nuclear circadian receptor RORα-dependent manner.
Ding S; Lin N; Sheng X; Zhao Y; Su Y; Xu L; Tong R; Yan Y; Fu Y; He J; Gao Y; Yuan A; Ye L; Reiter RJ; Pu J
J Pineal Res; 2019 Sep; 67(2):e12581. PubMed ID: 31009101
[TBL] [Abstract][Full Text] [Related]
6. MerTK receptor cleavage promotes plaque necrosis and defective resolution in atherosclerosis.
Cai B; Thorp EB; Doran AC; Sansbury BE; Daemen MJ; Dorweiler B; Spite M; Fredman G; Tabas I
J Clin Invest; 2017 Feb; 127(2):564-568. PubMed ID: 28067670
[TBL] [Abstract][Full Text] [Related]
7. Immunoproteasome subunit β5i regulates diet-induced atherosclerosis through altering MERTK-mediated efferocytosis in Apoe knockout mice.
Liao J; Xie Y; Lin Q; Yang X; An X; Xia Y; Du J; Wang F; Li HH
J Pathol; 2020 Mar; 250(3):275-287. PubMed ID: 31758542
[TBL] [Abstract][Full Text] [Related]
8. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis.
Doran AC; Ozcan L; Cai B; Zheng Z; Fredman G; Rymond CC; Dorweiler B; Sluimer JC; Hsieh J; Kuriakose G; Tall AR; Tabas I
J Clin Invest; 2017 Nov; 127(11):4075-4089. PubMed ID: 28972541
[TBL] [Abstract][Full Text] [Related]
9. Palmitoylethanolamide Promotes a Proresolving Macrophage Phenotype and Attenuates Atherosclerotic Plaque Formation.
Rinne P; Guillamat-Prats R; Rami M; Bindila L; Ring L; Lyytikäinen LP; Raitoharju E; Oksala N; Lehtimäki T; Weber C; van der Vorst EPC; Steffens S
Arterioscler Thromb Vasc Biol; 2018 Nov; 38(11):2562-2575. PubMed ID: 30354245
[TBL] [Abstract][Full Text] [Related]
10. Combination of tanshinone IIA and astragaloside IV attenuate atherosclerotic plaque vulnerability in ApoE(-/-) mice by activating PI3K/AKT signaling and suppressing TRL4/NF-κB signaling.
Wang N; Zhang X; Ma Z; Niu J; Ma S; Wenjie W; Chen J
Biomed Pharmacother; 2020 Mar; 123():109729. PubMed ID: 31887543
[TBL] [Abstract][Full Text] [Related]
11. HuoXueTongFu formula induces M2c macrophages via the MerTK/PI3K/AKT pathway to eliminate NETs in intraperitoneal adhesion in mice.
Zhao M; Chen Y; Bao X; Wang Z; Yuan N; Jin Z; Huang Y; Yang L; Yang Y; Zeng L
J Ethnopharmacol; 2024 Sep; 331():118290. PubMed ID: 38703872
[TBL] [Abstract][Full Text] [Related]
12. BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity.
Bae SH; Kim JH; Park TH; Lee K; Lee BI; Jang H
Exp Mol Med; 2022 Sep; 54(9):1450-1460. PubMed ID: 36056187
[TBL] [Abstract][Full Text] [Related]
13. Reversal of hypoxia in murine atherosclerosis prevents necrotic core expansion by enhancing efferocytosis.
Marsch E; Theelen TL; Demandt JA; Jeurissen M; van Gink M; Verjans R; Janssen A; Cleutjens JP; Meex SJ; Donners MM; Haenen GR; Schalkwijk CG; Dubois LJ; Lambin P; Mallat Z; Gijbels MJ; Heemskerk JW; Fisher EA; Biessen EA; Janssen BJ; Daemen MJ; Sluimer JC
Arterioscler Thromb Vasc Biol; 2014 Dec; 34(12):2545-53. PubMed ID: 25256233
[TBL] [Abstract][Full Text] [Related]
14. Elevated expression of macrophage MERTK exhibits profibrotic effects and results in defective regulation of efferocytosis function in pulmonary fibrosis.
She Y; Xu X; Yu Q; Yang X; He J; Tang XX
Respir Res; 2023 Apr; 24(1):118. PubMed ID: 37120511
[TBL] [Abstract][Full Text] [Related]
15. DBA/2J Haplotype on Distal Chromosome 2 Reduces Mertk Expression, Restricts Efferocytosis, and Increases Susceptibility to Atherosclerosis.
Kayashima Y; Makhanova N; Maeda N
Arterioscler Thromb Vasc Biol; 2017 Jul; 37(7):e82-e91. PubMed ID: 28473436
[TBL] [Abstract][Full Text] [Related]
16. Selective inhibition of PI3K/Akt/mTOR signaling pathway regulates autophagy of macrophage and vulnerability of atherosclerotic plaque.
Zhai C; Cheng J; Mujahid H; Wang H; Kong J; Yin Y; Li J; Zhang Y; Ji X; Chen W
PLoS One; 2014; 9(3):e90563. PubMed ID: 24599185
[TBL] [Abstract][Full Text] [Related]
17. K-80003 Inhibition of Macrophage Apoptosis and Necrotic Core Development in Atherosclerotic Vulnerable Plaques.
Wang X; Sun Z; Yuan R; Zhang W; Shen Y; Yin A; Li Y; Ji Q; Wang X; Li Y; Zhang M; Pan X; Shen L; He B
Cardiovasc Drugs Ther; 2022 Dec; 36(6):1061-1073. PubMed ID: 34410548
[TBL] [Abstract][Full Text] [Related]
18. Genetic Evidence Supports a Major Role for Akt1 in VSMCs During Atherogenesis.
Rotllan N; Wanschel AC; Fernández-Hernando A; Salerno AG; Offermanns S; Sessa WC; Fernández-Hernando C
Circ Res; 2015 May; 116(11):1744-52. PubMed ID: 25868464
[TBL] [Abstract][Full Text] [Related]
19. PM
Liang S; Sun Q; Du Z; Ren X; Xu Q; Sun Z; Duan J
Nanotoxicology; 2022 Apr; 16(3):290-309. PubMed ID: 35653618
[TBL] [Abstract][Full Text] [Related]
20.
Fang S; Sun S; Cai H; Zou X; Wang S; Hao X; Wan X; Tian J; Li Z; He Z; Huang W; Liang C; Zhang Z; Yang L; Tian J; Yu B; Sun B
Theranostics; 2021; 11(19):9358-9375. PubMed ID: 34646375
[No Abstract] [Full Text] [Related]
[Next] [New Search]
